287 related articles for article (PubMed ID: 31091466)
1. The multifaceted effects of metformin on tumor microenvironment.
Kurelac I; Umesh Ganesh N; Iorio M; Porcelli AM; Gasparre G
Semin Cell Dev Biol; 2020 Feb; 98():90-97. PubMed ID: 31091466
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol as a Tumor-Suppressive Nutraceutical Modulating Tumor Microenvironment and Malignant Behaviors of Cancer.
Han Y; Jo H; Cho JH; Dhanasekaran DN; Song YS
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791624
[TBL] [Abstract][Full Text] [Related]
3. Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells.
Qu H; Yang X
Cell Biochem Biophys; 2015 Mar; 71(2):931-6. PubMed ID: 25326336
[TBL] [Abstract][Full Text] [Related]
4. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
6. Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer.
Tsogas FK; Majerczyk D; Hart PC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467127
[TBL] [Abstract][Full Text] [Related]
7. Tumour macrophages as potential targets of bisphosphonates.
Rogers TL; Holen I
J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
9. Targeting angiogenesis and the tumor microenvironment.
Samples J; Willis M; Klauber-Demore N
Surg Oncol Clin N Am; 2013 Oct; 22(4):629-39. PubMed ID: 24012392
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
[TBL] [Abstract][Full Text] [Related]
11. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells.
Talarico G; Orecchioni S; Dallaglio K; Reggiani F; Mancuso P; Calleri A; Gregato G; Labanca V; Rossi T; Noonan DM; Albini A; Bertolini F
Sci Rep; 2016 Jan; 6():18673. PubMed ID: 26728433
[TBL] [Abstract][Full Text] [Related]
13. Impact of metformin on immunological markers: Implication in its anti-tumor mechanism.
Chen GG; Woo PYM; Ng SCP; Wong GKC; Chan DTM; van Hasselt CA; Tong MCF; Poon WS
Pharmacol Ther; 2020 Sep; 213():107585. PubMed ID: 32473961
[TBL] [Abstract][Full Text] [Related]
14. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies.
Chen P; Bonaldo P
Int Rev Cell Mol Biol; 2013; 301():1-35. PubMed ID: 23317816
[TBL] [Abstract][Full Text] [Related]
15. Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance.
Chiavarina B; Turtoi A
Curr Med Chem; 2017; 24(26):2846-2859. PubMed ID: 28462708
[TBL] [Abstract][Full Text] [Related]
16. Stromal Cells in the Tumor Microenvironment.
Denton AE; Roberts EW; Fearon DT
Adv Exp Med Biol; 2018; 1060():99-114. PubMed ID: 30155624
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C; Feron O
Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
[TBL] [Abstract][Full Text] [Related]
18. Metformin and cancer.
Rizos CV; Elisaf MS
Eur J Pharmacol; 2013 Apr; 705(1-3):96-108. PubMed ID: 23499688
[TBL] [Abstract][Full Text] [Related]
19. High dose targeted delivery on cancer sites and the importance of short-chain fatty acids for metformin's action: Two crucial aspects of the wonder drug.
Maniar K; Singh V; Chakrabarti A; Bhattacharyya R; Banerjee D
Regul Toxicol Pharmacol; 2018 Aug; 97():15-16. PubMed ID: 29857113
[TBL] [Abstract][Full Text] [Related]
20. Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts.
Chen G; Yu C; Tang Z; Liu S; An F; Zhu J; Wu Q; Cao J; Zhan Q; Zhang S
Oncol Rep; 2019 Jan; 41(1):405-414. PubMed ID: 30320344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
